FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy
Prostate Cancer Is the Second Leading Cause of Cancer Among Men in the U.S.
Published: 2023-06-23 - Updated: 2023-06-27
Author: Huntsman Cancer Institute - Contact: healthcare.utah.edu/huntsmancancerinstitute/
Peer-Reviewed: Yes - Publication Type: Clinical Trial
Journal Reference: DOI Link to the Study Paper
Related Papers: Latest Items - Full List
Synopsis: Research discovers major achievement in treatment of patients with prostate cancer and demonstrates how integration of clinical care and research directly translates into new treatment options for cancer patients. Prostate cancer is one of the most common cancers, according to the National Cancer Institute. It is also the second leading cause of cancer among men in the United States. The new treatment combines two cancer drugs, enzalutamide and talazoparib. While enzalutamide is a medication typically used for prostate cancer, the addition of talazoparib is new in patients with prostate cancer.
"Talazoparib Plus Enzalutamide in Men With First-Line Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-Controlled, Phase 3 Trial" - The Lancet.
Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, received approval by the U.S. Food and Drug Administration for a new prostate cancer treatment. This accomplishment comes shortly after he published the study in The Lancet, as the lead author, a first in institutional history.
The new treatment combines two cancer drugs, enzalutamide and talazoparib. While enzalutamide is a medication typically used for prostate cancer, the addition of talazoparib is new in patients with prostate cancer. In a phase 3 trial, this drug combination was found to decrease the risk of cancer progression by 55%, compared to the standard treatment in these patients for whom the FDA approved the combination.
"Getting this therapy approved means improved outcomes for many people," says Agarwal. "It is validation of our unwavering commitment to create and improve cancer treatments and to relieve the suffering of our patients."
"This work, led by Dr. Agarwal, with colleagues across the world is absolutely groundbreaking," says Neli Ulrich, PhD, chief scientific officer and executive director of the Comprehensive Cancer Center at Huntsman Cancer Institute. "It will make a big difference in treatment options for many prostate cancer patients."
Prostate cancer is one of the most common cancers, according to the National Cancer Institute. It is also the second leading cause of cancer among men in the United States.
"Research at Huntsman Cancer Institute, led by Dr. Agarwal, has resulted in a major achievement in the treatment of patients with prostate cancer," says Sachin Apte, MD, MS, MBA, chief clinical officer at Huntsman Cancer Institute. "This work demonstrates how the integration of clinical care and research directly translates into new treatment options for cancer patients."
Agarwal is a dedicated researcher and clinician. As senior director for clinical research translation, he oversees many early and advanced-phase clinical trials.
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the University of Utah is the official cancer center of Utah and the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West. The institute is leading the world in scientific discovery, and turning it into unsurpassed cancer care, transforming hope into a reality.
Huntsman Cancer Institute's scientists are world renown for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient's unique tumor. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.
Huntsman Cancer Institute has over 250 research teams and 200 clinical trials open to patients. Find a clinical trial or learn more by contacting the Cancer Learning Center.
This peer reviewed clinical trial article relating to our Prostate Cancer section was selected for publishing by the editors of Disabled World due to its likely interest to our disability community readers. Though the content may have been edited for style, clarity, or length, the article "FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy" was originally written by Huntsman Cancer Institute, and published by Disabled-World.com on 2023-06-23 (Updated: 2023-06-27). Should you require further information or clarification, Huntsman Cancer Institute can be contacted at healthcare.utah.edu/huntsmancancerinstitute/. Disabled World makes no warranties or representations in connection therewith.
Share This Information To:
𝕏.com Facebook Reddit
Discover Related Topics:
Information, Citing and Disclaimer
Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.
Permalink: <a href="https://www.disabled-world.com/health/cancer/prostate/enzalutamide-talazoparib.php">FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy</a>
Cite This Page (APA): Huntsman Cancer Institute. (2023, June 23). FDA Approves Enzalutamide Combined with Talazoparib for Prostate Cancer Therapy. Disabled World. Retrieved September 23, 2023 from www.disabled-world.com/health/cancer/prostate/enzalutamide-talazoparib.php
Disabled World provides general information only. The materials presented are never meant to substitute for qualified professional medical care, nor should they be construed as such. Funding is derived from advertisements or referral programs. Any 3rd party offering or advertising does not constitute an endorsement.